Daxor Corporation (NASDAQ:DXR) Short Interest Update

Key Points

• Daxor Corporation (NASDAQ:DXR) experienced a significant increase in short interest, rising by 774.6% from 6,300 shares to 55,100 shares in August.
• Renaissance Technologies LLC raised its stake in Daxor by 87.7% in the fourth quarter, owning 27,821 shares valued at $214,000, while institutional investors hold a total of 1.34% of the company’s stock.
• Daxor's stock price fell 2.5% to $11.00, with shares trading below the 50-day moving average of $10.04.

Daxor Corporation (NASDAQ:DXR - ) saw a large increase in short interest in August. As of August 15th, there was short interest totaling 55,100 shares, anincreaseof774.6% from the July 31st total of 6,300 shares. Based on an average daily volume of 27,500 shares, the short-interest ratio is currently 2.0 days. Approximately2.7% of the company's stock are short sold. Approximately2.7% of the company's stock are short sold. Based on an average daily volume of 27,500 shares, the short-interest ratio is currently 2.0 days.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Daxor stock. Renaissance Technologies LLC increased its position in shares of Daxor Corporation (NASDAQ:DXR - Free Report) by 87.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 27,821 shares of the company's stock after purchasing an additional 13,000 shares during the quarter. Renaissance Technologies LLC owned 0.57% of Daxor worth $214,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 1.34% of the company's stock.

Daxor Stock Down 2.5%

Shares of DXR stock traded down $0.28 during mid-day trading on Tuesday, reaching $11.00. 15,818 shares of the company were exchanged, compared to its average volume of 80,490. The business's 50 day simple moving average is $10.04 and its 200 day simple moving average is $8.67. Daxor has a fifty-two week low of $6.55 and a fifty-two week high of $11.38.

About Daxor

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.